Literature DB >> 9584216

An anionic residue at position 564 is important for maintaining the inactive conformation of the human lutropin/choriogonadotropin receptor.

S Kosugi1, T Mori, A Shenker.   

Abstract

Gonadotropin-independent, male-limited precocious puberty is caused by a variety of mutations in the lutropin/choriogonadotropin receptor (LHR) that produce constitutive receptor activation. Two of these mutations encode replacement of conserved aspartate residues at positions 564 and 578 with glycine. We previously used site-directed mutagenesis to study the functional role of the Asp578 side chain in transmembrane helix 6, and concluded that it is its ability to serve as a properly positioned interhelical hydrogen bond acceptor, rather than its negative charge, that is important for stabilizing the inactive state of the LHR. We now report the effects of substituting seven different amino acids for the Asp564 residue located at the carboxyl terminus of the third intracellular loop. Glycine, alanine, valine, leucine, phenylalanine, and asparagine produced constitutive activation in a COS-7 cell expression system (3-5-fold increase in basal cAMP), but glutamate did not, indicating that a negative charge at position 564 may be important for maintaining the inactive LHR conformation. Characterization of double-mutant receptors showed that certain substitutions at Asp564 and Asp578 have a cumulative effect on basal receptor activity, perhaps because they mimic different aspects of the activation process normally triggered by hormone binding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9584216

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

Review 1.  Naturally occurring mutations of the luteinizing-hormone receptor: lessons learned about reproductive physiology and G protein-coupled receptors.

Authors:  A C Latronico; D L Segaloff
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

Review 2.  Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Authors:  Michelle L Halls
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Potential Leydig cell mitogenic signals generated by the wild-type and constitutively active mutants of the lutropin/choriogonadotropin receptor (LHR).

Authors:  Mario Ascoli
Journal:  Mol Cell Endocrinol       Date:  2006-10-19       Impact factor: 4.102

4.  Conserved amino acids participate in the structure networks deputed to intramolecular communication in the lutropin receptor.

Authors:  Krassimira Angelova; Angelo Felline; Moon Lee; Manish Patel; David Puett; Francesca Fanelli
Journal:  Cell Mol Life Sci       Date:  2010-09-11       Impact factor: 9.261

5.  Structural determinants for G-protein activation and specificity in the third intracellular loop of the thyroid-stimulating hormone receptor.

Authors:  Maren Claus; Susanne Neumann; Gunnar Kleinau; Gerd Krause; Ralf Paschke
Journal:  J Mol Med (Berl)       Date:  2006-09-06       Impact factor: 4.599

6.  The third intracellular loop stabilizes the inactive state of the neuropeptide Y1 receptor.

Authors:  Melissa J S Chee; Karin Mörl; Diana Lindner; Nicole Merten; Gerald W Zamponi; Peter E Light; Annette G Beck-Sickinger; William F Colmers
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

Review 7.  A functional transmembrane complex: the luteinizing hormone receptor with bound ligand and G protein.

Authors:  D Puett; Y Li; G DeMars; K Angelova; F Fanelli
Journal:  Mol Cell Endocrinol       Date:  2006-10-23       Impact factor: 4.102

8.  An intracellular loop (IL2) residue confers different basal constitutive activities to the human lutropin receptor and human thyrotropin receptor through structural communication between IL2 and helix 6, via helix 3.

Authors:  Xiuyan Feng; Thomas Müller; Dario Mizrachi; Francesca Fanelli; Deborah L Segaloff
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.